Caracterización clínica, patológica y supervivencia global de neoplasias neuroendocrinas gastroenteropancreáticas de un centro de referencia, Bogotá-Colombia (2008-2020)

Introducción: Las neoplasias neuroendocrinas (NEN) son tumores raros y heterogéneos originados en el sistema neuroendocrino difuso, con comportamiento biológico y clínico variable. Representan el 0,5% de todas neoplasias recién diagnosticadas. Los tumores neuroendocrinos gastroenteropancreáticos (GE...

Full description

Autores:
Molina Pimienta, Luisana
Cuéllar Cuéllar , Andres A.
Tapiero Garcia, Mireya
Romero Rojas, Alfredo
Sanchez Castilla, Jesus Oswaldo
Tipo de recurso:
https://purl.org/coar/resource_type/c_7a1f
Fecha de publicación:
2025
Institución:
Universidad El Bosque
Repositorio:
Repositorio U. El Bosque
Idioma:
spa
OAI Identifier:
oai:repositorio.unbosque.edu.co:20.500.12495/13930
Acceso en línea:
https://hdl.handle.net/20.500.12495/13930
Palabra clave:
Supervivencia
Neoplasias neuroendocrinas
Epidemiología Clínica
Neuroendocrine Tumors
Survival
Clinical Epidemiology
QZ 200
Rights
License
Attribution-NonCommercial-ShareAlike 4.0 International
id UNBOSQUE2_c0035cf9b4403a49fecc2d35cdfcb047
oai_identifier_str oai:repositorio.unbosque.edu.co:20.500.12495/13930
network_acronym_str UNBOSQUE2
network_name_str Repositorio U. El Bosque
repository_id_str
dc.title.none.fl_str_mv Caracterización clínica, patológica y supervivencia global de neoplasias neuroendocrinas gastroenteropancreáticas de un centro de referencia, Bogotá-Colombia (2008-2020)
dc.title.translated.none.fl_str_mv Clinical and pathological characterization and overall survival of gastroenteropancreatic neuroendocrine neoplasms in Bogotá-Colombia (2008-2020)
title Caracterización clínica, patológica y supervivencia global de neoplasias neuroendocrinas gastroenteropancreáticas de un centro de referencia, Bogotá-Colombia (2008-2020)
spellingShingle Caracterización clínica, patológica y supervivencia global de neoplasias neuroendocrinas gastroenteropancreáticas de un centro de referencia, Bogotá-Colombia (2008-2020)
Supervivencia
Neoplasias neuroendocrinas
Epidemiología Clínica
Neuroendocrine Tumors
Survival
Clinical Epidemiology
QZ 200
title_short Caracterización clínica, patológica y supervivencia global de neoplasias neuroendocrinas gastroenteropancreáticas de un centro de referencia, Bogotá-Colombia (2008-2020)
title_full Caracterización clínica, patológica y supervivencia global de neoplasias neuroendocrinas gastroenteropancreáticas de un centro de referencia, Bogotá-Colombia (2008-2020)
title_fullStr Caracterización clínica, patológica y supervivencia global de neoplasias neuroendocrinas gastroenteropancreáticas de un centro de referencia, Bogotá-Colombia (2008-2020)
title_full_unstemmed Caracterización clínica, patológica y supervivencia global de neoplasias neuroendocrinas gastroenteropancreáticas de un centro de referencia, Bogotá-Colombia (2008-2020)
title_sort Caracterización clínica, patológica y supervivencia global de neoplasias neuroendocrinas gastroenteropancreáticas de un centro de referencia, Bogotá-Colombia (2008-2020)
dc.creator.fl_str_mv Molina Pimienta, Luisana
Cuéllar Cuéllar , Andres A.
Tapiero Garcia, Mireya
Romero Rojas, Alfredo
Sanchez Castilla, Jesus Oswaldo
dc.contributor.advisor.none.fl_str_mv Sanchez Castillo, Jesus Oswaldo
dc.contributor.author.none.fl_str_mv Molina Pimienta, Luisana
Cuéllar Cuéllar , Andres A.
Tapiero Garcia, Mireya
Romero Rojas, Alfredo
Sanchez Castilla, Jesus Oswaldo
dc.contributor.orcid.none.fl_str_mv Molina Pimienta, Luisana [0000-0001-5505-9710]
Cuéllar Cuéllar, Andres A. [0000-0002-1757-7952]
Tapiero Garcia, Tapiera [0000-0001-6342-0000]
Romero Rojas, Alfredo [0000-0003-0650-5731]
Sanchez Castilla, Jesus Oswaldo [0000-0001-8336-3066]
dc.subject.none.fl_str_mv Supervivencia
Neoplasias neuroendocrinas
Epidemiología Clínica
topic Supervivencia
Neoplasias neuroendocrinas
Epidemiología Clínica
Neuroendocrine Tumors
Survival
Clinical Epidemiology
QZ 200
dc.subject.keywords.none.fl_str_mv Neuroendocrine Tumors
Survival
Clinical Epidemiology
dc.subject.nlm.none.fl_str_mv QZ 200
description Introducción: Las neoplasias neuroendocrinas (NEN) son tumores raros y heterogéneos originados en el sistema neuroendocrino difuso, con comportamiento biológico y clínico variable. Representan el 0,5% de todas neoplasias recién diagnosticadas. Los tumores neuroendocrinos gastroenteropancreáticos (GEP-NEN) representan una proporción significativa de los NEN. Nuestro objetivo es establecer los factores clínicos y patológicos asociados a supervivencia de los pacientes con diagnóstico de GEP-NEN. Métodos: Observacional analítico tipo cohorte retrospectivo. Se incluyeron pacientes atendidos entre el 1 de enero de 20 y el 1 de enero de 2020 en el Instituto Nacional de Cancerología en Bogotá, Colombia. Resultados: Un total de 204 pacientes fueron incluidos. La mediana de edad fue de 55 años (rango: 46-64) y el 61,3% de los pacientes eran mujeres. La mayoría de los pacientes (95,6%) tenían tumores neuroendocrinos (TNE) gastroenteropancreáticos y el 55,9% tenía enfermedad en estadio IV. Además, el 30,9% tenía un tumor funcional. La mediana de seguimiento fue de 8,7 años (rango: 5,5 a 11,6 años). Aún no se ha alcanzado la mediana de supervivencia general. Se encontró una diferencia estadísticamente significativa en la supervivencia según la puntuación de Krenning (p = 0,023), el compromiso metastásico (p < 0,0001), el grado del tumor (p = 00093) y entre los pacientes sometidos a cirugía y los que no (p<0,0001). Conclusiones: En esta cohorte, los resultados de supervivencia fueron mayores que los informados anteriormente en México. Este estudio proporciona información valiosa sobre las GEP-NEN en un entorno de un país de ingresos medianos.
publishDate 2025
dc.date.accessioned.none.fl_str_mv 2025-02-11T21:59:00Z
dc.date.available.none.fl_str_mv 2025-02-11T21:59:00Z
dc.date.issued.none.fl_str_mv 2025-01
dc.type.coar.fl_str_mv http://purl.org/coar/resource_type/c_7a1f
dc.type.local.spa.fl_str_mv Tesis/Trabajo de grado - Monografía - Especialización
dc.type.coar.none.fl_str_mv https://purl.org/coar/resource_type/c_7a1f
dc.type.driver.none.fl_str_mv info:eu-repo/semantics/bachelorThesis
dc.type.coarversion.none.fl_str_mv https://purl.org/coar/version/c_ab4af688f83e57aa
format https://purl.org/coar/resource_type/c_7a1f
dc.identifier.uri.none.fl_str_mv https://hdl.handle.net/20.500.12495/13930
dc.identifier.instname.spa.fl_str_mv instname:Universidad El Bosque
dc.identifier.reponame.spa.fl_str_mv reponame:Repositorio Institucional Universidad El Bosque
dc.identifier.repourl.none.fl_str_mv repourl:https://repositorio.unbosque.edu.co
url https://hdl.handle.net/20.500.12495/13930
identifier_str_mv instname:Universidad El Bosque
reponame:Repositorio Institucional Universidad El Bosque
repourl:https://repositorio.unbosque.edu.co
dc.language.iso.fl_str_mv spa
language spa
dc.relation.references.none.fl_str_mv 1. Guo L-J, Wang C-H, Tang C-W. Epidemiological features of gastroenteropancreatic neuroendocrine tumors in Chengdu city with a population of 14 million based on data from a single institution. Asia Pac J Clin Oncol [Internet]. 2016 Sep;12(3):284–8. Available from: https://onlinelibrary.wiley.com/doi/10.1111/ajco.12498
2. Taal BG, Visser O. Epidemiology of Neuroendocrine Tumours. Neuroendocrinology [Internet]. 2004;80(Suppl. 1):3–7. Available from: https://www.karger.com/Article/FullText/80731
3. White BE, Rous B, Chandrakumaran K, Wong K, Bouvier C, Van Hemelrijck M, et al. Incidence and survival of neuroendocrine neoplasia in England 1995–2018: A retrospective, population-based study. Lancet Reg Heal - Eur [Internet]. 2022 Dec;23:100510. Available from: https://linkinghub.elsevier.com/retrieve/pii/S266677622200206X
4. Rindi G, Mete O, Uccella S, Basturk O, La Rosa S, Brosens LAA, et al. Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms. Endocr Pathol [Internet]. 2022 Mar 16;33(1):115–54. Available from: https://link.springer.com/10.1007/s12022-022-09708-2
5. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States. J Clin Oncol [Internet]. 2008 Jun 20;26(18):3063–72. Available from: https://ascopubs.org/doi/10.1200/JCO.2007.15.4377
6. O’Connor JM, Marmissolle F, Bestani C, Pesce V, Belli S, Dominichini E, et al. Observational study of patients with gastroenteropancreatic and bronchial neuroendocrine tumors in Argentina: Results from the large database of a multidisciplinary group clinical multicenter study. Mol Clin Oncol [Internet]. 2014 Sep;2(5):673–84. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25054030
7. Pinto MP, Muñoz Medel M, Carrillo D, Retamal IN, Bravo ML, Valenzuela Y, et al. Chilean Registry for Neuroendocrine Tumors: A Latin American Perspective. Horm Cancer [Internet]. 2019 Feb;10(1):3–10. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30465145
8. Escobar KM, Vicente-Villardon JL, Villacís Gonzalez RE, Castillo Cordova PH, Sánchez Rodríguez JM, De la Cruz-Velez M, et al. Neuroendocrine Tumors: An Analysis of Prevalence, Incidence, and Survival in a Hospital-Based Study in Ecuador. Healthc (Basel, Switzerland) [Internet]. 2022 Aug 18;10(8). Available from: http://www.ncbi.nlm.nih.gov/pubmed/36011226
9. Fierro-Maya LF, Prieto C, Garavito-G G, González-C AM, Muleth Y, Carreño JA. Resultados del tratamiento multidisciplinario de tumores neuroendocrinos de intestino delgado. Rev Colomb Cancerol [Internet]. 2018 Jul;22(3):105–11. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0123901518300593
10. Sorbye H, Strosberg J, Baudin E, Klimstra DS, Yao JC. Gastroenteropancreatic high-grade neuroendocrine carcinoma. Cancer [Internet]. 2014 Sep 15;120(18):2814–23. Available from: https://onlinelibrary.wiley.com/doi/10.1002/cncr.28721
11. Freis P, Graillot E, Rousset P, Hervieu V, Chardon L, Lombard-Bohas C, et al. Prognostic factors in neuroendocrine carcinoma: biological markers are more useful than histomorphological markers. Sci Rep [Internet]. 2017 Jan 11;7(1):40609. Available from: https://www.nature.com/articles/srep40609
12. Sakin A, Tambas M, Secmeler S, Can O, Arici S, Yasar N, et al. Factors Affecting Survival in Neuroendocrine Tumors: A 15-Year Single Center Experience. Asian Pacific J Cancer Prev [Internet]. 2018 Dec 1;19(12):3597–603. Available from: http://journal.waocp.org/article_77050.html
13. Nagtegaal ID, Odze RD, Klimstra D, Paradis V, Rugge M, Schirmacher P, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology [Internet]. 2020 Jan;76(2):182–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31433515
14. Chang JS, Chen L-T, Shan Y-S, Chu P-Y, Tsai C-R, Tsai H-J. An updated analysis of the epidemiologic trends of neuroendocrine tumors in Taiwan. Sci Rep [Internet]. 2021 Apr 12;11(1):7881. Available from: http://www.ncbi.nlm.nih.gov/pubmed/33846396
15. Rogoza O, Megnis K, Kudrjavceva M, Gerina-Berzina A, Rovite V. Role of Somatostatin Signalling in Neuroendocrine Tumours. Int J Mol Sci [Internet]. 2022 Jan 27;23(3). Available from: http://www.ncbi.nlm.nih.gov/pubmed/35163374
16. Mehta S, de Reuver PR, Gill P, Andrici J, D’Urso L, Mittal A, et al. Somatostatin Receptor SSTR-2a Expression Is a Stronger Predictor for Survival Than Ki-67 in Pancreatic Neuroendocrine Tumors. Medicine (Baltimore) [Internet]. 2015 Oct;94(40):e1281. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26447992
17. Falconi M, Eriksson B, Kaltsas G, Bartsch DK, Capdevila J, Caplin M, et al. ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors. Neuroendocrinology [Internet]. 2016;103(2):153–71. Available from: https://www.karger.com/Article/FullText/443171
18. Veenendaal LM, Borel Rinkes IHM, Lips CJM, van Hillegersberg R. Liver metastases of neuroendocrine tumours; early reduction of tumour load to improve life expectancy. World J Surg Oncol [Internet]. 2006 Jun 26;4:35. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16800893
19. Pavel M, Öberg K, Falconi M, Krenning EP, Sundin A, Perren A, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol [Internet]. 2020 Jul;31(7):844–60. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0923753420363948
20. Foubert F, Salimon M, Dumars C, Regenet N, Girot P, Venara A, et al. Survival and prognostic factors analysis of 151 intestinal and pancreatic neuroendocrine tumors: a single center experience. J Gastrointest Oncol [Internet]. 2018 Feb;10(1):103–11. Available from: http://jgo.amegroups.com/article/view/25092/19704
21. Sorbye H, Welin S, Langer SW, Vestermark LW, Holt N, Osterlund P, et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study. Ann Oncol [Internet]. 2013 Jan;24(1):152–60. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0923753419370486
22. Poleé IN, Hermans BCM, van der Zwan JM, Bouwense SAW, Dercksen MW, Eskens FALM, et al. Long-term survival in patients with gastroenteropancreatic neuroendocrine neoplasms: A population-based study. Eur J Cancer [Internet]. 2022 Sep;172:252–63. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0959804922003409
23. Pellat A, Cottereau AS, Terris B, Coriat R. Neuroendocrine Carcinomas of the Digestive Tract: What Is New? Cancers (Basel) [Internet]. 2021 Jul 27;13(15):3766. Available from: https://www.mdpi.com/2072-6694/13/15/3766
24. Uccella S, La Rosa S, Metovic J, Marchiori D, Scoazec J-Y, Volante M, et al. Genomics of High-Grade Neuroendocrine Neoplasms: Well-Differentiated Neuroendocrine Tumor with High-Grade Features (G3 NET) and Neuroendocrine Carcinomas (NEC) of Various Anatomic Sites. Endocr Pathol [Internet]. 2021 Mar;32(1):192–210. Available from: http://www.ncbi.nlm.nih.gov/pubmed/33433884
25. Korse CM, Taal BG, van Velthuysen M-LF, Visser O. Incidence and survival of neuroendocrine tumours in the Netherlands according to histological grade: Experience of two decades of cancer registry. Eur J Cancer [Internet]. 2013 May;49(8):1975–83. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0959804912010313
26. Dasari A, Mehta K, Byers LA, Sorbye H, Yao JC. Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: A SEER database analysis of 162,983 cases. Cancer [Internet]. 2018 Feb 15;124(4):807–15. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29211313
27. Alese OB, Jiang R, Shaib W, Wu C, Akce M, Behera M, et al. High-Grade Gastrointestinal Neuroendocrine Carcinoma Management and Outcomes: A National Cancer Database Study. Oncologist [Internet]. 2019 Jul;24(7):911–20. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30482824
28. Lamarca A, Walter T, Pavel M, Borbath I, Freis P, Nuñez B, et al. Design and Validation of the GI-NEC Score to Prognosticate Overall Survival in Patients With High-Grade Gastrointestinal Neuroendocrine Carcinomas. J Natl Cancer Inst [Internet]. 2017 Jan;109(5). Available from: http://www.ncbi.nlm.nih.gov/pubmed/28130474
29. Milione M, Maisonneuve P, Spada F, Pellegrinelli A, Spaggiari P, Albarello L, et al. The Clinicopathologic Heterogeneity of Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: Morphological Differentiation and Proliferation Identify Different Prognostic Categories. Neuroendocrinology [Internet]. 2017;104(1):85–93. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26943788
30. Torres-Cisneros ER, Burguete-Torres A, Buenaventura Cisneros S, Bruni-Guerrero CR, Wimer-Castillo BO, Hernández-Barajas D, et al. Neuroendocrine tumors: Ten years of experience in a Mexican oncology reference center. J Clin Oncol [Internet]. 2022 Feb 1;40(4_suppl):503–503. Available from: https://ascopubs.org/doi/10.1200/JCO.2022.40.4_suppl.503
31. Magi L, Mazzuca F, Rinzivillo M, Arrivi G, Pilozzi E, Prosperi D, et al. Multidisciplinary Management of Neuroendocrine Neoplasia: A Real-World Experience from a Referral Center. J Clin Med [Internet]. 2019 Jun 25;8(6):910. Available from: https://www.mdpi.com/2077-0383/8/6/910
32. Zandee WT, Merola E, Poczkaj K, de Mestier L, Klümpen H, Geboes K, et al. Evaluation of multidisciplinary team decisions in neuroendocrine neoplasms: Impact of expert centres. Eur J Cancer Care (Engl) [Internet]. 2022 Nov 23;31(6). Available from: https://onlinelibrary.wiley.com/doi/10.1111/ecc.13639
33. Basuroy R, Bouvier C, Ramage JK, Sissons M, Srirajaskanthan R. Delays and routes to diagnosis of neuroendocrine tumours. BMC Cancer [Internet]. 2018 Nov 16;18(1):1122. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30445941
34. Singh S, Granberg D, Wolin E, Warner R, Sissons M, Kolarova T, et al. Patient-Reported Burden of a Neuroendocrine Tumor (NET) Diagnosis: Results From the First Global Survey of Patients With NETs. J Glob Oncol [Internet]. 2017 Feb;3(1):43–53. Available from: https://ascopubs.org/doi/10.1200/JGO.2015.002980
35. Xu Z, Wang L, Dai S, Chen M, Li F, Sun J, et al. Epidemiologic Trends of and Factors Associated With Overall Survival for Patients With Gastroenteropancreatic Neuroendocrine Tumors in the United States. JAMA Netw Open [Internet]. 2021 Sep 23;4(9):e2124750. Available from: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2784437
36. Tan B, Zhang B, Chen H. Gastroenteropancreatic neuroendocrine neoplasms: epidemiology, genetics, and treatment. Front Endocrinol (Lausanne) [Internet]. 2024 Sep 30;15. Available from: https://www.frontiersin.org/articles/10.3389/fendo.2024.1424839/full
37. Estrozi B, Bacchi CE. Neuroendocrine tumors involving the gastroenteropancreatic tract: a clinicopathological evaluation of 773 cases. Clinics (Sao Paulo) [Internet]. 2011;66(10):1671–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22012036
38. Neychev V, Kebebew E. Management Options for Advanced Low or Intermediate Grade Gastroenteropancreatic Neuroendocrine Tumors: Review of Recent Literature. Int J Surg Oncol [Internet]. 2017;2017:1–14. Available from: https://www.hindawi.com/journals/ijso/2017/6424812/
39. Fernandez CJ, Agarwal M, Pottakkat B, Haroon NN, George AS, Pappachan JM. Gastroenteropancreatic neuroendocrine neoplasms: A clinical snapshot. World J Gastrointest Surg [Internet]. 2021 Mar 27;13(3):231–55. Available from: https://www.wjgnet.com/1948-9366/full/v13/i3/231.htm
40. Haeger A, Soza-Ried C, Kramer V, Hurtado de Mendoza A, Eppard E, Emmanuel N, et al. Al[18F]F-NOTA-Octreotide Is Comparable to [68Ga]Ga-DOTA-TATE for PET/CT Imaging of Neuroendocrine Tumours in the Latin-American Population. Cancers (Basel) [Internet]. 2023 Jan 10;15(2). Available from: http://www.ncbi.nlm.nih.gov/pubmed/36672388
41. Garcia-Carbonero R, Capdevila J, Crespo-Herrero G, Díaz-Pérez JA, Martínez del Prado MP, Alonso Orduña V, et al. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Ann Oncol [Internet]. 2010 Sep;21(9):1794–803. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0923753419400483
42. De Souza ZS, Xavier CB, Gomes LBM, de Medeiros MFB, de Sousa MC, Pereira AAL, et al. Survival and Response Outcomes for Gastrointestinal Neuroendocrine Tumor (GEP-NETs) Patients Treated with Lutetium—177-DOTATATE in a Brazilian Reference Center: A Six-Year Follow-Up Experience. Cancers (Basel) [Internet]. 2023 Sep 11;15(18):4506. Available from: https://www.mdpi.com/2072-6694/15/18/4506
dc.rights.en.fl_str_mv Attribution-NonCommercial-ShareAlike 4.0 International
dc.rights.coar.fl_str_mv http://purl.org/coar/access_right/c_abf2
dc.rights.uri.none.fl_str_mv http://creativecommons.org/licenses/by-nc-sa/4.0/
dc.rights.local.spa.fl_str_mv Acceso abierto
dc.rights.accessrights.none.fl_str_mv https://purl.org/coar/access_right/c_abf2
rights_invalid_str_mv Attribution-NonCommercial-ShareAlike 4.0 International
http://creativecommons.org/licenses/by-nc-sa/4.0/
Acceso abierto
https://purl.org/coar/access_right/c_abf2
http://purl.org/coar/access_right/c_abf2
dc.format.mimetype.none.fl_str_mv application/pdf
dc.publisher.program.spa.fl_str_mv Especialización en Oncología Clínica
dc.publisher.grantor.spa.fl_str_mv Universidad El Bosque
dc.publisher.faculty.spa.fl_str_mv Facultad de Medicina
institution Universidad El Bosque
bitstream.url.fl_str_mv https://repositorio.unbosque.edu.co/bitstreams/a05b9347-12db-4807-89f2-990f7da84b49/download
https://repositorio.unbosque.edu.co/bitstreams/615143dd-2346-4f4a-bb32-dbe954f41446/download
https://repositorio.unbosque.edu.co/bitstreams/3ae74a47-726d-404a-bd47-0796f8758213/download
https://repositorio.unbosque.edu.co/bitstreams/e4c8c8f4-0286-4091-b71a-42c6eb11ea06/download
https://repositorio.unbosque.edu.co/bitstreams/9ff05ff4-ffcd-427b-8942-f0182ade26a2/download
https://repositorio.unbosque.edu.co/bitstreams/7def2d8c-faac-4742-bacb-583d3579184c/download
https://repositorio.unbosque.edu.co/bitstreams/1675e0d0-6f5b-4c74-9369-ef6744116ddf/download
bitstream.checksum.fl_str_mv 2309b7aec65173207e8bdfce7d975225
17cc15b951e7cc6b3728a574117320f9
69e2f4a12c739334fd879a33fc0d8545
8aa5092e9171b3552a3cebd56a69d9e2
5643bfd9bcf29d560eeec56d584edaa9
ded0fa62854f59f400288d4198cdc431
bfbd620cfb79f398f027d3cb9c0a4e52
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
MD5
MD5
MD5
repository.name.fl_str_mv Repositorio Institucional Universidad El Bosque
repository.mail.fl_str_mv bibliotecas@biteca.com
_version_ 1828164542390075392
spelling Sanchez Castillo, Jesus OswaldoMolina Pimienta, LuisanaCuéllar Cuéllar , Andres A.Tapiero Garcia, MireyaRomero Rojas, AlfredoSanchez Castilla, Jesus OswaldoMolina Pimienta, Luisana [0000-0001-5505-9710]Cuéllar Cuéllar, Andres A. [0000-0002-1757-7952]Tapiero Garcia, Tapiera [0000-0001-6342-0000]Romero Rojas, Alfredo [0000-0003-0650-5731]Sanchez Castilla, Jesus Oswaldo [0000-0001-8336-3066]2025-02-11T21:59:00Z2025-02-11T21:59:00Z2025-01https://hdl.handle.net/20.500.12495/13930instname:Universidad El Bosquereponame:Repositorio Institucional Universidad El Bosquerepourl:https://repositorio.unbosque.edu.coIntroducción: Las neoplasias neuroendocrinas (NEN) son tumores raros y heterogéneos originados en el sistema neuroendocrino difuso, con comportamiento biológico y clínico variable. Representan el 0,5% de todas neoplasias recién diagnosticadas. Los tumores neuroendocrinos gastroenteropancreáticos (GEP-NEN) representan una proporción significativa de los NEN. Nuestro objetivo es establecer los factores clínicos y patológicos asociados a supervivencia de los pacientes con diagnóstico de GEP-NEN. Métodos: Observacional analítico tipo cohorte retrospectivo. Se incluyeron pacientes atendidos entre el 1 de enero de 20 y el 1 de enero de 2020 en el Instituto Nacional de Cancerología en Bogotá, Colombia. Resultados: Un total de 204 pacientes fueron incluidos. La mediana de edad fue de 55 años (rango: 46-64) y el 61,3% de los pacientes eran mujeres. La mayoría de los pacientes (95,6%) tenían tumores neuroendocrinos (TNE) gastroenteropancreáticos y el 55,9% tenía enfermedad en estadio IV. Además, el 30,9% tenía un tumor funcional. La mediana de seguimiento fue de 8,7 años (rango: 5,5 a 11,6 años). Aún no se ha alcanzado la mediana de supervivencia general. Se encontró una diferencia estadísticamente significativa en la supervivencia según la puntuación de Krenning (p = 0,023), el compromiso metastásico (p < 0,0001), el grado del tumor (p = 00093) y entre los pacientes sometidos a cirugía y los que no (p<0,0001). Conclusiones: En esta cohorte, los resultados de supervivencia fueron mayores que los informados anteriormente en México. Este estudio proporciona información valiosa sobre las GEP-NEN en un entorno de un país de ingresos medianos.Instituto Nacional de CancerologíaEspecialista en Oncología ClínicaEspecializaciónBackground Neuroendocrine neoplasms (NEN) are rare and heterogeneous tumors originating in the diffuse neuroendocrine system, with variable biological and clinical behavior, representing about 0.5% of all newly diagnosed neoplasms globally. Gastroenteropancreatic neuroendocrine tumors (GEP-NEN) account for a significant proportion of NENs. This study aimed to establish the clinical and pathological factors associated with survival in patients diagnosed with GEP-NEN. Methods: This was an observational, retrospective cohort study. Patients diagnosed and treated between January 1, 2020, and January 1, 2021, at the National Cancer Institute in Bogotá, Colombia, were included. Results: A total of 204 patients were included. The median age was 55 years (range: 46-64), and 61.3% of patients were women. Most patients (95.6%) had GEP-NEN, and 55.9% had stage IV disease. Additionally, 30.9% had a functional tumor. The median follow-up was 8.7 years (range: 5.5–11.6 years). The median overall survival has not yet been reached. A statistically significant difference in survival was found by Krenning score (p=0.023), metastatic involvement (p<0.0001), tumor grade (p=0.00093) and between patients who underwent surgery at the primary site and those who did not (p<0.0001). Conclusions: In this cohort, survival outcomes were higher than those previously reported in Mexico. This study provides valuable information about GEP-NEN in a middle-income country setting.application/pdfAttribution-NonCommercial-ShareAlike 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-sa/4.0/Acceso abiertohttps://purl.org/coar/access_right/c_abf2http://purl.org/coar/access_right/c_abf2SupervivenciaNeoplasias neuroendocrinasEpidemiología ClínicaNeuroendocrine TumorsSurvivalClinical EpidemiologyQZ 200Caracterización clínica, patológica y supervivencia global de neoplasias neuroendocrinas gastroenteropancreáticas de un centro de referencia, Bogotá-Colombia (2008-2020)Clinical and pathological characterization and overall survival of gastroenteropancreatic neuroendocrine neoplasms in Bogotá-Colombia (2008-2020)Especialización en Oncología ClínicaUniversidad El BosqueFacultad de MedicinaTesis/Trabajo de grado - Monografía - Especializaciónhttps://purl.org/coar/resource_type/c_7a1fhttp://purl.org/coar/resource_type/c_7a1finfo:eu-repo/semantics/bachelorThesishttps://purl.org/coar/version/c_ab4af688f83e57aa1. Guo L-J, Wang C-H, Tang C-W. Epidemiological features of gastroenteropancreatic neuroendocrine tumors in Chengdu city with a population of 14 million based on data from a single institution. Asia Pac J Clin Oncol [Internet]. 2016 Sep;12(3):284–8. Available from: https://onlinelibrary.wiley.com/doi/10.1111/ajco.124982. Taal BG, Visser O. Epidemiology of Neuroendocrine Tumours. Neuroendocrinology [Internet]. 2004;80(Suppl. 1):3–7. Available from: https://www.karger.com/Article/FullText/807313. White BE, Rous B, Chandrakumaran K, Wong K, Bouvier C, Van Hemelrijck M, et al. Incidence and survival of neuroendocrine neoplasia in England 1995–2018: A retrospective, population-based study. Lancet Reg Heal - Eur [Internet]. 2022 Dec;23:100510. Available from: https://linkinghub.elsevier.com/retrieve/pii/S266677622200206X4. Rindi G, Mete O, Uccella S, Basturk O, La Rosa S, Brosens LAA, et al. Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms. Endocr Pathol [Internet]. 2022 Mar 16;33(1):115–54. Available from: https://link.springer.com/10.1007/s12022-022-09708-25. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States. J Clin Oncol [Internet]. 2008 Jun 20;26(18):3063–72. Available from: https://ascopubs.org/doi/10.1200/JCO.2007.15.43776. O’Connor JM, Marmissolle F, Bestani C, Pesce V, Belli S, Dominichini E, et al. Observational study of patients with gastroenteropancreatic and bronchial neuroendocrine tumors in Argentina: Results from the large database of a multidisciplinary group clinical multicenter study. Mol Clin Oncol [Internet]. 2014 Sep;2(5):673–84. Available from: http://www.ncbi.nlm.nih.gov/pubmed/250540307. Pinto MP, Muñoz Medel M, Carrillo D, Retamal IN, Bravo ML, Valenzuela Y, et al. Chilean Registry for Neuroendocrine Tumors: A Latin American Perspective. Horm Cancer [Internet]. 2019 Feb;10(1):3–10. Available from: http://www.ncbi.nlm.nih.gov/pubmed/304651458. Escobar KM, Vicente-Villardon JL, Villacís Gonzalez RE, Castillo Cordova PH, Sánchez Rodríguez JM, De la Cruz-Velez M, et al. Neuroendocrine Tumors: An Analysis of Prevalence, Incidence, and Survival in a Hospital-Based Study in Ecuador. Healthc (Basel, Switzerland) [Internet]. 2022 Aug 18;10(8). Available from: http://www.ncbi.nlm.nih.gov/pubmed/360112269. Fierro-Maya LF, Prieto C, Garavito-G G, González-C AM, Muleth Y, Carreño JA. Resultados del tratamiento multidisciplinario de tumores neuroendocrinos de intestino delgado. Rev Colomb Cancerol [Internet]. 2018 Jul;22(3):105–11. Available from: https://linkinghub.elsevier.com/retrieve/pii/S012390151830059310. Sorbye H, Strosberg J, Baudin E, Klimstra DS, Yao JC. Gastroenteropancreatic high-grade neuroendocrine carcinoma. Cancer [Internet]. 2014 Sep 15;120(18):2814–23. Available from: https://onlinelibrary.wiley.com/doi/10.1002/cncr.2872111. Freis P, Graillot E, Rousset P, Hervieu V, Chardon L, Lombard-Bohas C, et al. Prognostic factors in neuroendocrine carcinoma: biological markers are more useful than histomorphological markers. Sci Rep [Internet]. 2017 Jan 11;7(1):40609. Available from: https://www.nature.com/articles/srep4060912. Sakin A, Tambas M, Secmeler S, Can O, Arici S, Yasar N, et al. Factors Affecting Survival in Neuroendocrine Tumors: A 15-Year Single Center Experience. Asian Pacific J Cancer Prev [Internet]. 2018 Dec 1;19(12):3597–603. Available from: http://journal.waocp.org/article_77050.html13. Nagtegaal ID, Odze RD, Klimstra D, Paradis V, Rugge M, Schirmacher P, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology [Internet]. 2020 Jan;76(2):182–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/3143351514. Chang JS, Chen L-T, Shan Y-S, Chu P-Y, Tsai C-R, Tsai H-J. An updated analysis of the epidemiologic trends of neuroendocrine tumors in Taiwan. Sci Rep [Internet]. 2021 Apr 12;11(1):7881. Available from: http://www.ncbi.nlm.nih.gov/pubmed/3384639615. Rogoza O, Megnis K, Kudrjavceva M, Gerina-Berzina A, Rovite V. Role of Somatostatin Signalling in Neuroendocrine Tumours. Int J Mol Sci [Internet]. 2022 Jan 27;23(3). Available from: http://www.ncbi.nlm.nih.gov/pubmed/3516337416. Mehta S, de Reuver PR, Gill P, Andrici J, D’Urso L, Mittal A, et al. Somatostatin Receptor SSTR-2a Expression Is a Stronger Predictor for Survival Than Ki-67 in Pancreatic Neuroendocrine Tumors. Medicine (Baltimore) [Internet]. 2015 Oct;94(40):e1281. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2644799217. Falconi M, Eriksson B, Kaltsas G, Bartsch DK, Capdevila J, Caplin M, et al. ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors. Neuroendocrinology [Internet]. 2016;103(2):153–71. Available from: https://www.karger.com/Article/FullText/44317118. Veenendaal LM, Borel Rinkes IHM, Lips CJM, van Hillegersberg R. Liver metastases of neuroendocrine tumours; early reduction of tumour load to improve life expectancy. World J Surg Oncol [Internet]. 2006 Jun 26;4:35. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1680089319. Pavel M, Öberg K, Falconi M, Krenning EP, Sundin A, Perren A, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol [Internet]. 2020 Jul;31(7):844–60. Available from: https://linkinghub.elsevier.com/retrieve/pii/S092375342036394820. Foubert F, Salimon M, Dumars C, Regenet N, Girot P, Venara A, et al. Survival and prognostic factors analysis of 151 intestinal and pancreatic neuroendocrine tumors: a single center experience. J Gastrointest Oncol [Internet]. 2018 Feb;10(1):103–11. Available from: http://jgo.amegroups.com/article/view/25092/1970421. Sorbye H, Welin S, Langer SW, Vestermark LW, Holt N, Osterlund P, et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study. Ann Oncol [Internet]. 2013 Jan;24(1):152–60. Available from: https://linkinghub.elsevier.com/retrieve/pii/S092375341937048622. Poleé IN, Hermans BCM, van der Zwan JM, Bouwense SAW, Dercksen MW, Eskens FALM, et al. Long-term survival in patients with gastroenteropancreatic neuroendocrine neoplasms: A population-based study. Eur J Cancer [Internet]. 2022 Sep;172:252–63. Available from: https://linkinghub.elsevier.com/retrieve/pii/S095980492200340923. Pellat A, Cottereau AS, Terris B, Coriat R. Neuroendocrine Carcinomas of the Digestive Tract: What Is New? Cancers (Basel) [Internet]. 2021 Jul 27;13(15):3766. Available from: https://www.mdpi.com/2072-6694/13/15/376624. Uccella S, La Rosa S, Metovic J, Marchiori D, Scoazec J-Y, Volante M, et al. Genomics of High-Grade Neuroendocrine Neoplasms: Well-Differentiated Neuroendocrine Tumor with High-Grade Features (G3 NET) and Neuroendocrine Carcinomas (NEC) of Various Anatomic Sites. Endocr Pathol [Internet]. 2021 Mar;32(1):192–210. Available from: http://www.ncbi.nlm.nih.gov/pubmed/3343388425. Korse CM, Taal BG, van Velthuysen M-LF, Visser O. Incidence and survival of neuroendocrine tumours in the Netherlands according to histological grade: Experience of two decades of cancer registry. Eur J Cancer [Internet]. 2013 May;49(8):1975–83. Available from: https://linkinghub.elsevier.com/retrieve/pii/S095980491201031326. Dasari A, Mehta K, Byers LA, Sorbye H, Yao JC. Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: A SEER database analysis of 162,983 cases. Cancer [Internet]. 2018 Feb 15;124(4):807–15. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2921131327. Alese OB, Jiang R, Shaib W, Wu C, Akce M, Behera M, et al. High-Grade Gastrointestinal Neuroendocrine Carcinoma Management and Outcomes: A National Cancer Database Study. Oncologist [Internet]. 2019 Jul;24(7):911–20. Available from: http://www.ncbi.nlm.nih.gov/pubmed/3048282428. Lamarca A, Walter T, Pavel M, Borbath I, Freis P, Nuñez B, et al. Design and Validation of the GI-NEC Score to Prognosticate Overall Survival in Patients With High-Grade Gastrointestinal Neuroendocrine Carcinomas. J Natl Cancer Inst [Internet]. 2017 Jan;109(5). Available from: http://www.ncbi.nlm.nih.gov/pubmed/2813047429. Milione M, Maisonneuve P, Spada F, Pellegrinelli A, Spaggiari P, Albarello L, et al. The Clinicopathologic Heterogeneity of Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: Morphological Differentiation and Proliferation Identify Different Prognostic Categories. Neuroendocrinology [Internet]. 2017;104(1):85–93. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2694378830. Torres-Cisneros ER, Burguete-Torres A, Buenaventura Cisneros S, Bruni-Guerrero CR, Wimer-Castillo BO, Hernández-Barajas D, et al. Neuroendocrine tumors: Ten years of experience in a Mexican oncology reference center. J Clin Oncol [Internet]. 2022 Feb 1;40(4_suppl):503–503. Available from: https://ascopubs.org/doi/10.1200/JCO.2022.40.4_suppl.50331. Magi L, Mazzuca F, Rinzivillo M, Arrivi G, Pilozzi E, Prosperi D, et al. Multidisciplinary Management of Neuroendocrine Neoplasia: A Real-World Experience from a Referral Center. J Clin Med [Internet]. 2019 Jun 25;8(6):910. Available from: https://www.mdpi.com/2077-0383/8/6/91032. Zandee WT, Merola E, Poczkaj K, de Mestier L, Klümpen H, Geboes K, et al. Evaluation of multidisciplinary team decisions in neuroendocrine neoplasms: Impact of expert centres. Eur J Cancer Care (Engl) [Internet]. 2022 Nov 23;31(6). Available from: https://onlinelibrary.wiley.com/doi/10.1111/ecc.1363933. Basuroy R, Bouvier C, Ramage JK, Sissons M, Srirajaskanthan R. Delays and routes to diagnosis of neuroendocrine tumours. BMC Cancer [Internet]. 2018 Nov 16;18(1):1122. Available from: http://www.ncbi.nlm.nih.gov/pubmed/3044594134. Singh S, Granberg D, Wolin E, Warner R, Sissons M, Kolarova T, et al. Patient-Reported Burden of a Neuroendocrine Tumor (NET) Diagnosis: Results From the First Global Survey of Patients With NETs. J Glob Oncol [Internet]. 2017 Feb;3(1):43–53. Available from: https://ascopubs.org/doi/10.1200/JGO.2015.00298035. Xu Z, Wang L, Dai S, Chen M, Li F, Sun J, et al. Epidemiologic Trends of and Factors Associated With Overall Survival for Patients With Gastroenteropancreatic Neuroendocrine Tumors in the United States. JAMA Netw Open [Internet]. 2021 Sep 23;4(9):e2124750. Available from: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/278443736. Tan B, Zhang B, Chen H. Gastroenteropancreatic neuroendocrine neoplasms: epidemiology, genetics, and treatment. Front Endocrinol (Lausanne) [Internet]. 2024 Sep 30;15. Available from: https://www.frontiersin.org/articles/10.3389/fendo.2024.1424839/full37. Estrozi B, Bacchi CE. Neuroendocrine tumors involving the gastroenteropancreatic tract: a clinicopathological evaluation of 773 cases. Clinics (Sao Paulo) [Internet]. 2011;66(10):1671–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2201203638. Neychev V, Kebebew E. Management Options for Advanced Low or Intermediate Grade Gastroenteropancreatic Neuroendocrine Tumors: Review of Recent Literature. Int J Surg Oncol [Internet]. 2017;2017:1–14. Available from: https://www.hindawi.com/journals/ijso/2017/6424812/39. Fernandez CJ, Agarwal M, Pottakkat B, Haroon NN, George AS, Pappachan JM. Gastroenteropancreatic neuroendocrine neoplasms: A clinical snapshot. World J Gastrointest Surg [Internet]. 2021 Mar 27;13(3):231–55. Available from: https://www.wjgnet.com/1948-9366/full/v13/i3/231.htm40. Haeger A, Soza-Ried C, Kramer V, Hurtado de Mendoza A, Eppard E, Emmanuel N, et al. Al[18F]F-NOTA-Octreotide Is Comparable to [68Ga]Ga-DOTA-TATE for PET/CT Imaging of Neuroendocrine Tumours in the Latin-American Population. Cancers (Basel) [Internet]. 2023 Jan 10;15(2). Available from: http://www.ncbi.nlm.nih.gov/pubmed/3667238841. Garcia-Carbonero R, Capdevila J, Crespo-Herrero G, Díaz-Pérez JA, Martínez del Prado MP, Alonso Orduña V, et al. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Ann Oncol [Internet]. 2010 Sep;21(9):1794–803. Available from: https://linkinghub.elsevier.com/retrieve/pii/S092375341940048342. De Souza ZS, Xavier CB, Gomes LBM, de Medeiros MFB, de Sousa MC, Pereira AAL, et al. Survival and Response Outcomes for Gastrointestinal Neuroendocrine Tumor (GEP-NETs) Patients Treated with Lutetium—177-DOTATATE in a Brazilian Reference Center: A Six-Year Follow-Up Experience. Cancers (Basel) [Internet]. 2023 Sep 11;15(18):4506. Available from: https://www.mdpi.com/2072-6694/15/18/4506spaORIGINALTrabajo de grado.pdfapplication/pdf740444https://repositorio.unbosque.edu.co/bitstreams/a05b9347-12db-4807-89f2-990f7da84b49/download2309b7aec65173207e8bdfce7d975225MD57LICENSElicense.txtlicense.txttext/plain; charset=utf-82000https://repositorio.unbosque.edu.co/bitstreams/615143dd-2346-4f4a-bb32-dbe954f41446/download17cc15b951e7cc6b3728a574117320f9MD53Carta de autorizacion.pdfapplication/pdf483208https://repositorio.unbosque.edu.co/bitstreams/3ae74a47-726d-404a-bd47-0796f8758213/download69e2f4a12c739334fd879a33fc0d8545MD55Anexo 1 Acta de aprobacion.pdfapplication/pdf178924https://repositorio.unbosque.edu.co/bitstreams/e4c8c8f4-0286-4091-b71a-42c6eb11ea06/download8aa5092e9171b3552a3cebd56a69d9e2MD56CC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-81160https://repositorio.unbosque.edu.co/bitstreams/9ff05ff4-ffcd-427b-8942-f0182ade26a2/download5643bfd9bcf29d560eeec56d584edaa9MD54TEXTTrabajo de grado.pdf.txtTrabajo de grado.pdf.txtExtracted texttext/plain72749https://repositorio.unbosque.edu.co/bitstreams/7def2d8c-faac-4742-bacb-583d3579184c/downloadded0fa62854f59f400288d4198cdc431MD58THUMBNAILTrabajo de grado.pdf.jpgTrabajo de grado.pdf.jpgGenerated Thumbnailimage/jpeg3153https://repositorio.unbosque.edu.co/bitstreams/1675e0d0-6f5b-4c74-9369-ef6744116ddf/downloadbfbd620cfb79f398f027d3cb9c0a4e52MD5920.500.12495/13930oai:repositorio.unbosque.edu.co:20.500.12495/139302025-02-12 03:06:55.298http://creativecommons.org/licenses/by-nc-sa/4.0/Attribution-NonCommercial-ShareAlike 4.0 Internationalembargo2026-02-11https://repositorio.unbosque.edu.coRepositorio Institucional Universidad El Bosquebibliotecas@biteca.com

Publicaciones similares